Drugs in early clinical development for Systemic Lupus Erythematosus.

ABSTRACT:

Introduction

While immunosuppressive therapy has positively impacted the prognosis of systemic lupus erythematosus (SLE), many patients still do not respond to traditional therapy. Thus, active SLE disease remains a significant problem. Furthermore, conventional immunosuppressive treatments for SLE are associated a high risk of side effects. These issues call for improvement in our current therapeutic armamentarium.

Areas covered

In this review, the authors highlight the recent developments in therapies for SLE, and present an overview of drugs which are in early clinical development for SLE. There are many new therapeutic approaches being developed, including those focused on B-cell targets, T-cell downregulation, co-stimulatory blockade, anti-cytokine agents, and kinase in

SUBMITTER: Postal M 

PROVIDER: S-EPMC5056793 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature